Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation
Published in: NewsWire
Date: 28 February 2018
Philogen S.p.A. Announces Authorization From FDA Of A Pivotal Registration Trial In U.S.A. For The Treatment Of Resectable Melanoma
Published in: BioSpace
Date: 12 October 2017
Philogen S.p.A. Announces Research Collaboration With Servier n The Field Of DNA-Encoded Chemistry
Published in: BioSpace
Date: 25 August 2017
Boehringer Ingelheim to Leverage Philogen’s DNA-Encoded Library Platform
Published in: Inside Precision Medicine
Date: 20 July 2017
Philogen S.p.A. Announces Exercise Of Options Within The License Agreement With Pfizer For The Development And Potential Commercialization Of Multiple Antibody Drug Conjugates (ADCs) And Targeted Technologies
Published in: CNN Money
Date: 21 January 2016
Philogen S.p.A. Announces Commencement Of Phase III Pivotal Trial In Melanoma
Published in: BioSpace
Date: 21 January 2016
Philogen S.p.A. Announces Collaboration With Johnson & Johnson Innovation
Published in: BioSpace
Date: 3 August 2016
Philogen S.p.A. Announces Expanded Research And Development Agreement With AbbVie
Published in: BioSpace
Date: 15 February 2016
Italy’s Philogen signs drug licence deal with Pfizer
Published in: Reuters
Date: 3 January 2013